Data updates from the ongoing Phase 1 dose-escalation study demonstrated promising therapeutic index in patients with mCRPC No dose-limiting toxicities observed; xerostomia has been predominantly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results